Palisade Bio Provides Update on U.S. Phase 2 Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions

Topline data readout from study expected in first half of 2023

Excerpt from the Press Release:

Carlsbad, CA, Dec. 16, 2022 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is providing an update on its U.S. Phase 2 study evaluating LB1148 for reduction in intra-abdominal adhesions in subjects following elective bowel resection (PROFILE).

The Company enrolled a total of 35 of the planned 70 patients in its Phase 2 study. Of the patients enrolled, 31 have completed their first surgery, and nine have completed a second surgery, which is an inflection point for data under the current study protocol. Palisade believes that the data collected to date is sufficient for its evaluation purposes, including an evaluation of its risk profile, and for such reason, the Company is voluntarily ceasing enrollment in the trial. Palisade expects to report topline data from the 35 patients in the first half of 2023.

Herbert B. Slade, MD, FAAAAI, Chief Medical Officer of Palisade Bio stated, “We are optimistic about the topline data expected in the first half of 2023 related to the achievement of the primary endpoint of the Phase 2 adhesions study. We remain encouraged by the data demonstrated by LB1148 and are committed to driving its development in a manner that we believe best positions us to provide patient benefit, and ultimately approval.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release